Africa
In a quiet but groundbreaking move, the Global Fund to Fight AIDS, Tuberculosis and Malaria announced the procurement of a first-line HIV treatment manufactured on African soil—for the first time in its history. Produced in Kenya by Universal Corporation, this treatment is set to reach 72,000 people annually in Mozambique.
While it may seem a logistical footnote to some, this milestone marks a powerful turning point for Africa. It represents not only scientific excellence but also economic assertion and continental solidarity. Africa is stepping forward with a clear message: We are the architects of our own future.
Sixty years after gaining political independence, many African nations remain economically and technologically dependent—especially in the pharmaceutical sector. Although Africa bears the highest global burden of HIV, the continent has historically imported 70% to 90% of its medicines. More than 25 million Africans living with HIV rely on daily antiretroviral therapy. Ensuring sovereign, consistent, and affordable access to treatment is not optional—it’s urgent.
This procurement signals a shift toward local pharmaceutical manufacturing, not just for HIV treatment but for broader health needs—from tuberculosis and malaria to non-communicable diseases and pandemic preparedness. It is a pivotal step toward achieving the Africa CDC’s goal of producing 60% of the continent’s vaccine needs locally by 2040, as envisioned by the Partnerships for African Vaccine Manufacturing.
Local drug manufacturing brings more than health benefits—it unlocks economic transformation. When medicines are imported, African governments incur additional costs in shipping, import duties, and inflated pricing. Local production can drastically reduce these expenses.
African manufacturers, rooted in their communities, understand local price sensitivities and can help drive down treatment costs. With scaled production, Africa strengthens its negotiating power in the global pharmaceutical arena, challenging monopolies and securing better procurement deals.
A homegrown pharmaceutical industry also fuels job creation, skills development, and regional trade. It builds a value chain that includes engineers, scientists, quality assurance specialists, and logisticians—redirecting procurement spend into African economies and strengthening resilience against global supply disruptions like those witnessed during the COVID-19 pandemic.
This procurement must not remain an isolated event. It should serve as a catalyst for systemic reform across the continent. Four key shifts are needed:
- Institutionalise Local Procurement
Donors like the Global Fund and Unitaid must make local sourcing the norm, not the exception. African pharmaceutical producers in South Africa, Nigeria, Ghana, Senegal, and beyond must be integrated into global supply chains, provided they meet standards of quality and cost-effectiveness. - African Governments Must Invest, Not Just Advocate
Local demand drives local growth. Governments must commit to buying locally—not just for exports, but for national health programmes. Tax incentives, research subsidies, and infrastructure support are essential to expand pharmaceutical capabilities. - Accelerate Regional Regulatory Harmonisation
The African Medicines Agency must prioritise mutual recognition of regulatory approvals across borders. Removing duplicative barriers is vital to building a dynamic continental pharmaceutical market. - Accountability Through Civil Society
Transparent procurement decisions are crucial. Civil society has a role to play in ensuring that qualified African suppliers are prioritised and that donor funds do not unjustly flow to overseas companies when local alternatives exist.
For generations, Africa has supplied the world—its minerals, its people, and its ideas. Now, the continent is reclaiming its power in healthcare. With this historic procurement, the Global Fund has not just bought medication; it has helped rewrite the script of global health equity.
This is not the end of the story—it is the beginning. A moment of continental self-determination, economic agency, and public health leadership.
